Pharming Group (PHAR) Competitors $14.76 +0.10 (+0.65%) Closing price 10/8/2025 03:55 PM EasternExtended Trading$14.73 -0.04 (-0.24%) As of 10/8/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAR vs. ADMA, SRRK, MIRM, ACAD, ZLAB, AAPG, LNTH, TLX, INDV, and NAMSShould you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include ADMA Biologics (ADMA), Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), ACADIA Pharmaceuticals (ACAD), Zai Lab (ZLAB), Ascentage Pharma Group International (AAPG), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Indivior (INDV), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Pharming Group vs. Its Competitors ADMA Biologics Scholar Rock Mirum Pharmaceuticals ACADIA Pharmaceuticals Zai Lab Ascentage Pharma Group International Lantheus Telix Pharmaceuticals Indivior NewAmsterdam Pharma ADMA Biologics (NASDAQ:ADMA) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends. Does the media prefer ADMA or PHAR? In the previous week, Pharming Group had 8 more articles in the media than ADMA Biologics. MarketBeat recorded 11 mentions for Pharming Group and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.84 beat Pharming Group's score of 0.26 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in ADMA or PHAR? 75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 3.5% of ADMA Biologics shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher earnings & valuation, ADMA or PHAR? ADMA Biologics has higher revenue and earnings than Pharming Group. Pharming Group is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADMA Biologics$426.45M8.18$197.67M$0.8617.00Pharming Group$339.84M2.98-$11.84M-$0.13-113.58 Which has more volatility and risk, ADMA or PHAR? ADMA Biologics has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500. Do analysts rate ADMA or PHAR? ADMA Biologics presently has a consensus price target of $27.67, suggesting a potential upside of 89.24%. Pharming Group has a consensus price target of $30.00, suggesting a potential upside of 103.18%. Given Pharming Group's higher probable upside, analysts plainly believe Pharming Group is more favorable than ADMA Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Pharming Group 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Is ADMA or PHAR more profitable? ADMA Biologics has a net margin of 44.06% compared to Pharming Group's net margin of -2.19%. ADMA Biologics' return on equity of 41.01% beat Pharming Group's return on equity.Company Net Margins Return on Equity Return on Assets ADMA Biologics44.06% 41.01% 28.47% Pharming Group -2.19%-3.31%-1.78% SummaryADMA Biologics beats Pharming Group on 14 of the 16 factors compared between the two stocks. Get Pharming Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAR vs. The Competition Export to ExcelMetricPharming GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.01B$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-113.5821.5785.3527.60Price / Sales2.98271.49539.78202.41Price / Cash197.9047.1237.9261.55Price / Book4.5410.1413.016.76Net Income-$11.84M-$52.31M$3.30B$275.88M7 Day Performance-1.53%5.14%4.34%2.81%1 Month Performance-0.71%14.68%9.49%9.24%1 Year Performance70.69%30.98%84.83%35.42% Pharming Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHARPharming Group2.3081 of 5 stars$14.77+0.6%$30.00+103.2%+69.5%$1.01B$339.84M-113.58280Analyst ForecastShort Interest ↑ADMAADMA Biologics3.6779 of 5 stars$14.70-5.8%$27.67+88.2%-29.4%$3.73B$426.45M17.09530Analyst ForecastSRRKScholar Rock4.655 of 5 stars$38.36-1.0%$46.40+21.0%+31.2%$3.72B$33.19M-13.18140Positive NewsAnalyst ForecastInsider TradeGap UpMIRMMirum Pharmaceuticals3.3309 of 5 stars$72.85+0.1%$76.50+5.0%+87.2%$3.66B$336.89M-60.21140Positive NewsAnalyst ForecastACADACADIA Pharmaceuticals4.4719 of 5 stars$21.32+1.3%$29.12+36.6%+47.4%$3.55B$957.80M16.03510Analyst RevisionZLABZai Lab2.553 of 5 stars$32.93+4.1%$56.35+71.1%+35.6%$3.53B$398.99M-16.141,869News CoveragePositive NewsAnalyst ForecastAAPGAscentage Pharma Group InternationalN/A$38.55+3.3%N/AN/A$3.48B$134.35M0.00600LNTHLantheus4.6478 of 5 stars$50.62+0.0%$85.50+68.9%-50.5%$3.44B$1.53B13.46700Trending NewsAnalyst ForecastGap DownTLXTelix Pharmaceuticals4.4741 of 5 stars$9.89-0.9%$21.00+112.3%N/A$3.38B$516.72M0.00N/AAnalyst UpgradeINDVIndivior2.9558 of 5 stars$24.10+0.8%$22.00-8.7%+145.1%$3.30B$1.17B38.871,051News CoverageAnalyst ForecastNAMSNewAmsterdam Pharma3.1863 of 5 stars$27.52-3.4%$42.00+52.6%+85.2%$3.21B$64.01M-16.994Analyst Forecast Related Companies and Tools Related Companies ADMA Competitors SRRK Competitors MIRM Competitors ACAD Competitors ZLAB Competitors AAPG Competitors LNTH Competitors TLX Competitors INDV Competitors NAMS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAR) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group N.V. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
